For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>KM11060 is a novel corrector of the F508del-CFTR trafficking defect.<br>Target: CFTR<br>in vitro: Small-molecule correctors such as KM11060 may serve as useful pharmacological tools in studies of the F508del-CFTR processing defect and in the development of cystic fibrosis therapeutics. KM11060 rescues F508del-CFTR trafficking in cultured cells and native epithelial tissues. KM11060 partially corrects F508del-CFTR processing and increases surface expression to 75% of that observed in cells incubated at low temperature. Up to 50% of the F508del-CFTR in cells treated with KM11060 was complex-glycosylated, indicating passage through the Golgi. KM11060 as a promising compound for further development of CF therapeutics. [1]<br>in vivo: In LPS-induced acute lung inflammation, blockade of PSGL-1 (P-selectin glycoprotein ligand-1) or P-selectin, antagonism of PAF by WEB2086, or correction of mutated CFTR trafficking by KM11060 could significantly increase plasma lipoxin A4 levels in F508del relevant to wildtype mice. [2]</p>
| Catalog Number | I004848 |
| CAS Number | 774549-97-2 |
| Synonyms | 7-chloro-4-(4-((4-chlorophenyl)sulfonyl)piperazin-1-yl)quinoline |
| Molecular Formula | C19H17Cl2N3O2S |
| Purity | ≥95% |
| Target | Chloride Channels |
| Solubility | 10 mM in DMSO |
| Storage | Store at RT |
| InChI | InChI=1S/C19H17Cl2N3O2S/c20-14-1-4-16(5-2-14)27(25,26)24-11-9-23(10-12-24)19-7-8-22-18-13-15(21)3-6-17(18)19/h1-8,13H,9-12H2 |
| InChIKey | GIEHIZKCIZLXLF-UHFFFAOYSA-N |
| SMILES | O=S(N1CCN(C2=CC=NC3=CC(Cl)=CC=C23)CC1)(C4=CC=C(Cl)C=C4)=O |
| Reference | <p style=/line-height:25px/> <br>[2]. Wu H, et al. Lipoxin A4 and platelet activating factor are involved in E. coli or LPS-induced lung inflammation in CFTR-deficient mice. PLoS One. 2014 Mar 26;9(3):e93003. </p> |
